Tritonpoint Wealth Trims Regeneron Pharmaceuticals Stake

Investment firm reduces holding in biotech company by 70% in Q4

Apr. 5, 2026 at 11:26am

Got story updates? Submit your updates here. ›

Tritonpoint Wealth LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 70% during the fourth quarter, according to a recent SEC filing. The investment firm now owns 829 shares of the biopharmaceutical company's stock, down from 2,767 shares previously.

Why it matters

Regeneron Pharmaceuticals is a major player in the biotech industry, known for its innovative drug discovery technologies. Institutional investor moves can provide insights into market sentiment and future performance expectations for the company.

The details

Tritonpoint Wealth sold 1,938 shares of Regeneron Pharmaceuticals stock during the fourth quarter, leaving the firm with a remaining holding of 829 shares valued at $640,000. The reduction represents a 70% decrease in Tritonpoint's position in the biotech company.

  • Tritonpoint Wealth made the stock sale during the fourth quarter of 2025.
  • The firm previously owned 2,767 shares of Regeneron Pharmaceuticals.

The players

Tritonpoint Wealth LLC

An investment management firm that reduced its stake in Regeneron Pharmaceuticals by 70% in Q4 2025.

Regeneron Pharmaceuticals, Inc.

A U.S. biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

Tritonpoint Wealth's decision to significantly trim its Regeneron Pharmaceuticals holdings could signal a shift in market sentiment around the biotech firm, though the reasons behind the portfolio adjustment remain unclear. Investors will likely monitor Regeneron's performance and any further changes in institutional ownership.